[1]
|
Smolen, J.S., Aletaha, D. and Mcinnes, I.B. (2016) Rheumatoid Arthritis. Lancet, 388, 2023-2038.
https://doi.org/10.1016/S0140-6736(16)30173-8
|
[2]
|
周静, 张弦, 钱海兵. 类风湿性关节炎发病机制的研究进展[J]. 贵阳中医学院学报, 2014, 36(5): 44-47.
|
[3]
|
王绍文, 余林健, 万晓春, 等. 类风湿性关节炎免疫发病机制的研究进展[J]. 集成技术, 2015, 4(4): 64-73.
|
[4]
|
伍斌, 鲁延富, 姜凤良. 类风湿关节炎发病机制的研究进展[J]. 医学综述, 2014, 20(23): 4249-4251.
|
[5]
|
Zampeli, E., Vlachoyiannopoulos, P.G. and Tzioufas, A.G. (2015) Treatment of Rheumatoid Arthritis: Unraveling the Conundrum. Journal of Autoimmunity, 65, 1-18. https://doi.org/10.1016/j.jaut.2015.10.003
|
[6]
|
Smolen, J.S., Breedveld, F.C., Burmester, G.R., et al. (2016) Treat-ing Rheumatoid Arthritis to Target: 2014 Update of the Recommendations of an International Task Force. Annals of the Rheumatic Diseases, 75, 3-15.
https://doi.org/10.1136/annrheumdis-2015-207524
|
[7]
|
Favalli, E.G., Raimondo, M.G., Becciolini, A., et al. (2017) The Management of First-Line Biologic Therapy Failures in Rheumatoid Arthritis: Current Practice and Future Perspec-tives. Autoimmunity Reviews, 16, 1185-1195.
https://doi.org/10.1016/j.autrev.2017.10.002
|
[8]
|
Favalli, E.G., Pregnolato, F., Biggioggero, M., et al. (2016) Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data from a Local Registry. Arthritis Care & Research (Hoboken), 68, 432-439. https://doi.org/10.1002/acr.22788
|
[9]
|
陈玥. 白细胞介素-6抑制药治疗类风湿关节炎的研究进展[J]. 医药导报, 2017, 36(6): 646-649.
|
[10]
|
Abdel Meguid, M.H., Hamad, Y.H., Swilam, R.S., et al. (2013) Relation of Interleukin-6 in Rheumatoid Arthritis Patients to Systemic Bone Loss and Structural Bone Damage. Rheumatology International, 33, 697-703.
https://doi.org/10.1007/s00296-012-2375-7
|
[11]
|
于雪, 季强. 单克隆抗体治疗免疫疾病的研究进展[J]. 天津药学, 2015, 27(2): 70-72.
|
[12]
|
戴莉萍, 何伟珍, 孔卫红, 等. 托珠单抗治疗难治性类风湿关节炎患者的效[J]. 中国医药导报, 2014, 11(22): 60.
|
[13]
|
Dougados, M., Kissel, K., Sheeran, T., et al. (2013) Adding Tocilizumab or Switching to Tocilizumab Monotherapy in Methotrexate Inadequate Responders: 24-Week Symptomatic and Structural Results of a 2-Year Randomised Controlled Strategy Trial in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 72, 43.
https://doi.org/10.1136/annrheumdis-2011-201282
|
[14]
|
史群, 赵岩, 鲍春德, 等. 托珠单抗联合改善病情抗风湿药治疗类风湿关节炎的多中心、随机、双盲、安慰剂对照临床研究[J]. 中华内科杂志, 2013, 52(4): 323 -329.
|
[15]
|
Kremer, J.M., Blanco, R., Brzosko, M., et al. (2011) Tocilizumab Inhibits Structural Joint Damage in Rheu-matoid Arthritis Patients with Inadequate Responses to Methotrexate: Results from the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year. Arthritis & Rheumatology, 63, 609-621. https://doi.org/10.1002/art.30158
|
[16]
|
Nishimoto, N., Ito, K. and Takagi, N. (2010) Safety and Efficacy Profiles of Tocilizumab Monotherapy in Japanese Patients with Rheumatoid Arthritis: Meta-Analysis of Six Initial Trials and Five Long-Term Extensions. Modern Rheumatology, 20, 222-232. https://doi.org/10.3109/s10165-010-0279-5
|
[17]
|
Gabay, C., Riek, M., Hetland, M.L., et al. (2016) Effectiveness of Tocilizumab with and without Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results from a European Collaborative Study. Annals of the Rheumatic Diseases, 75, 1336-1342. https://doi.org/10.1136/annrheumdis-2015-207760
|
[18]
|
Singh, J.A., Saag, K.G., Bridges Jr., S.L., et al. (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology, 68, 1-26. https://doi.org/10.1002/art.39480
|
[19]
|
Smolen, J.S., Landewé, R., Breedveld, F.C., et al. (2017) EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying An-tirheumatic Drugs: 2016 Update. Annals of the Rheumatic Diseases, 76, 960-977. https://doi.org/10.1136/annrheumdis-2016-210715
|
[20]
|
Raimondo, M.G., Biggioggero, M. and Crotti, C. (2017) Profile of Sarilumab and Its Potential in the Treatment of Rheumatoid Arthritis. Drug Design, Development and Therapy, 11, 1593-1603.
https://doi.org/10.2147/DDDT.S100302
|
[21]
|
Takeuchi, T., Thorne, C., Karpouzas, G., et al. (2017) Sirukumab for Rheumatoid Arthritis: The Phase III SIRROUND-D Study. Annals of the Rheumatic Diseases, 76, 2001-2008.
https://doi.org/10.1136/annrheumdis-2017-211328
|
[22]
|
Shaw, S., Bourne, T., Meier, C., et al. (2014) Discovery and Characterization of Olokizumab: A Humanized Antibody Targeting Interleukin-6 and Neutralizing gp130-Signaling. mAbs, 6, 774-781. https://doi.org/10.4161/mabs.28612
|
[23]
|
Mease, P.J., Gottlieb, A.B., Berman, A., et al. (2016) The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults with Active Psoriatic Arthritis. Arthritis & Rheumatology, 68, 2163-2173. https://doi.org/10.1002/art.39700
|
[24]
|
Sanofi, Regeneron Pharmaceuticals Inc. (2017) Sanofi and Regeneron An-nounce First Approval of KevzaraTM (Sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthri-tis in Adult Patients by Health Canada.
http://www.sanofi-aventis.com
|
[25]
|
Sanofi US. (2017) Sanofi and Regeneron Announce FDA Approval of Kevzara® (Sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients.
http://www.news.sanofi.us/2017-05-22-Sanofi-and-Regeneron-Announce-FDA-Approval-of-Kevzara-R-Sarilumab-forthe-Treatment-of-Moderately-to-Severely-Active-RheumatoidArthritis-in-Adult-Patients
|
[26]
|
Rafque, A., Martin, J., Blome, M., Huang, T., Ouyang, A. and Papadopoulos, N. (2013) Evaluation of the Binding Kinetics and Functional Bi-oassay Activity of Sarilumab and Tocilizumab to the Human IL-6 Receptor (IL-6R) Alpha. Annals of the Rheumatic Diseases, 72, A797. https://doi.org/10.1136/annrheumdis-2013-eular.2360
|
[27]
|
Hunter, C.A. and Jones, S.A. (2015) IL-6 as a Keystone Cytokine in Health and Disease. Nature Immunology, 16, 448-457. https://doi.org/10.1038/ni.3153
|
[28]
|
Calabrese, L.H. and Rose-John, S. (2014) IL-6 Biology: Implications for Clinical Targeting in Rheumatic Disease. Nature Reviews Rheumatology, 10, 720-727. https://doi.org/10.1038/nrrheum.2014.127
|
[29]
|
Lee, E.B. (2018) A Review of Sarilumab for the Treatment of Rheumatoid Arthritis. Immunotherapy, 10, 57-65.
https://doi.org/10.2217/imt-2017-0075
|
[30]
|
Boyce, E.G., Rogan, E.L., Vyas, D., Prasad, N. and Mai, Y. (2018) Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis. Annals of Pharmacotherapy, 52, 780-791.
https://doi.org/10.1177/1060028018761599
|
[31]
|
Aly, A.M. and Furst, D.E. (2017) Update of Sarilumab to Treat Rheumatoid Arthritis Based on Randomized Clinical Trials: A Systematic Review. Expert Review of Clinical Immunology, 3, 741-752.
https://doi.org/10.1080/1744666X.2017.1351297
|
[32]
|
Sanofi-aventis Canada Inc. (2017) KevzaraTM (Sarilumab): Product Monograph (Canada).
http://pdf.hres.ca/dpd_pm/00037766.PDF
|
[33]
|
Scott, L.J. (2017) Sarilumab: First Global Approval. Drugs, 77, 705-712. https://doi.org/10.1007/s40265-017-0724-2
|
[34]
|
Huizinga, T.W., Fleischmann, R.M., Jasson, M., et al. (2014) Sarilumab, a Fully Human Monoclonal Antibody against IL-6Rα in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Efficacy and Safety Results from the Randomized SARIL-RA-MOBILITY Part A Trial. Annals of the Rheumatic Diseases, 73, 1626-1634.
https://doi.org/10.1136/annrheumdis-2013-204405
|
[35]
|
Genovese, M.C., Fleischmann, R., Kivitz, A.J., et al. (2015) Sarilumab plus Methotrexate in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis & Rheumatology, 67, 1424-1437. https://doi.org/10.1002/art.39093
|
[36]
|
Fleischmann, R., Van Adelsberg, J., Lin, Y., et al. (2017) Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active Rheumatoid Arthritis and Inadequate Re-sponse or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis & Rheumatology, 69, 277-290. https://doi.org/10.1002/art.39944
|
[37]
|
Burmester, G.R., Lin, Y., Patel, R., et al. (2017) Efficacy and Safety of Sarilumab Monotherapy versus Adalimumab Monotherapy for the Treatment of Patients with Active Rheumatoid Arthri-tis (MONARCH): A Randomised, Double-Blind, Parallel-Group Phase III Trial. Annals of the Rheumatic Diseases, 76, 840-847.
https://doi.org/10.1136/annrheumdis-2016-210310
|
[38]
|
Gabay, C., Emery, P., Van Vollenhoven, R., et al. (2013) Tocilizumab Monotherapy versus Adalimumab Monotherapy for Treatment of Rheumatoid Arthritis (ADACTA): A Randomised, Double-Blind, Controlled Phase IV Trial. The Lancet, 381, 1541-1550. https://doi.org/10.1016/S0140-6736(13)60250-0
|
[39]
|
Mccarty, D. and Robinson, A. (2018) Efficacy and Safety of Sarilumab in Patients with Active Rheumatoid Arthritis. Therapeutic Advances in Musculoskeletal Disease, 10, 61-67. https://doi.org/10.1177/1759720X17752037
|
[40]
|
Fleischmann, R., Genovese, M.C., Van Adelsberg, J., et al. (2016) Pooled Safety and Efficacy of Sarilumab in Rheumatoid Arthritis Patients 65 Years of Age and Older. Arthritis & Rheumatology, 68.
|
[41]
|
European Medicines Agency (2017) Kevzara INN-Sarilumab. Assessment Report from the Committee for Medicinal Products for Human Use. Procedure No. EMEA/H/C/004254/0000.
|
[42]
|
US Food and Drug Administration (2017) Sarilumab Resubmission: Response to FDA Complete Response Letter. Center for Drug Evalua-tion & Research. Reference ID: 4099025.
|
[43]
|
Regeneron Pharmaceuticals Inc./Sanofi-aventis US LLC. Kevzara (Pack-age Insert). New York/New Jersey: Regeneron Pharmaceuticals Inc./Sanofi-aventis US LLC (2017). http://products.sanofi.us/kevzara/kevzara.pdf
|